- Sprache
-
Englisch
- Umfang
-
Online-Ressource
- Anmerkungen
-
Heidelberg, Universität Heidelberg, Dissertation, 2023
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Urheber
- Beteiligte Personen und Organisationen
-
Miller, Aubry K.
- Ereignis
-
Veröffentlichung
- (wo)
-
Heidelberg
- (wer)
-
Universitätsbibliothek Heidelberg
- (wann)
-
2023
- DOI
-
10.11588/heidok.00033158
- URN
-
urn:nbn:de:bsz:16-heidok-331582
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:48 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Steimbach, Raphael R.
- Miller, Aubry K.
- Universitätsbibliothek Heidelberg
Entstanden
- 2023
Ähnliche Objekte (12)
Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
Development of class IIa histone deacetylase inhibitors
Histone deacetylase inhibitor valproic acid in pancreas differentiation
Targeting aberrant histone acetylation in cancer: development of class I selective histone deacetylase (HDAC) inhibitors and dual HDAC/BET bromodomain inhibitors
Histone deacetylase inhibitors regulate the proteasomal degradation of oncoproteins
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Sensitization by histone deacetylase inhibitors of receptor mediated hepatic apoptosis
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Synthesis and characterisation of novel isoform-selective histone deacetylase inhibitors (HDACi) and HDACi-based multi-target ligands
Differentiation therapy of childhood neuroblastoma through selective inhibition of histone deacetylase 8
Senzitization of glioblastoma to TRAIL-induced apoptosis by histone deacetylase inhibitors
Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
Development of class IIa histone deacetylase inhibitors
Histone deacetylase inhibitor valproic acid in pancreas differentiation
Targeting aberrant histone acetylation in cancer: development of class I selective histone deacetylase (HDAC) inhibitors and dual HDAC/BET bromodomain inhibitors
Histone deacetylase inhibitors regulate the proteasomal degradation of oncoproteins
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Sensitization by histone deacetylase inhibitors of receptor mediated hepatic apoptosis
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Synthesis and characterisation of novel isoform-selective histone deacetylase inhibitors (HDACi) and HDACi-based multi-target ligands
Differentiation therapy of childhood neuroblastoma through selective inhibition of histone deacetylase 8
Senzitization of glioblastoma to TRAIL-induced apoptosis by histone deacetylase inhibitors
Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
Development of class IIa histone deacetylase inhibitors
Histone deacetylase inhibitor valproic acid in pancreas differentiation
Targeting aberrant histone acetylation in cancer: development of class I selective histone deacetylase (HDAC) inhibitors and dual HDAC/BET bromodomain inhibitors
Histone deacetylase inhibitors regulate the proteasomal degradation of oncoproteins
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Sensitization by histone deacetylase inhibitors of receptor mediated hepatic apoptosis
Balancing Histone Deacetylase (HDAC) Inhibition and Druglikeness : Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Synthesis and characterisation of novel isoform-selective histone deacetylase inhibitors (HDACi) and HDACi-based multi-target ligands
Differentiation therapy of childhood neuroblastoma through selective inhibition of histone deacetylase 8